eFinder

eFinder

Home › Market Valuation › Article

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

Cnbc · · 389 words · By Liz Napolitano
Market Valuation Investment Opportunity Pharmaceutical Pipeline
open_in_new Read the original article: https://www.cnbc.com/2026/04/22/this-pharmaceutical-stock-is-cheap-relative-to-p…

psychologyDetected Techniques

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.

fact_checkFact-Check Results

10 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

check_circle Corroborated 4
verified Verified By Reference 3
help Insufficient Evidence 3
check_circle
“The investment bank [UBS] upgraded the pharmaceutical name to buy from neutral.”
CORROBORATED
Two independent web sources confirm that UBS upgraded Biogen's stock rating from 'Neutral' to 'Buy'.
travel_explore
web search NEUTRAL — Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price target to $225 from $185, citing growing confidence in a series of clinical a…
https://ca.finance.yahoo.com/news/biogen-upgraded-ubs-slew-p…
travel_explore
web search NEUTRAL — In terms of analyst activity, UBS upgraded Biogen’s stock rating from Neutral to Buy, raising the price target to $225 due to potential pipeline catalysts. H.C. Wainwright also increased its price tar…
https://in.investing.com/news/stock-market-news/bofa-raises-…
travel_explore
web search NEUTRAL — Key PointsCanaccord upgraded Biogen to buy from hold.UBS upgraded Chipotle to neutral from sell.
https://www.cnbc.com/2020/01/27/mondays-analyst-calls-of-the…
check_circle
“It also hiked its price target on shares to $225 from $185”
CORROBORATED
Two independent web sources confirm that UBS raised the price target for Biogen from $185 to $225.
menu_book
wikipedia NEUTRAL — The Dow Jones Sustainability Indices (DJSI) launched in 1999, are a family of indices evaluating the sustainability performance of thousands of companies trading publicly, operated under a strategic p…
https://en.wikipedia.org/wiki/Dow_Jones_Sustainability_Indic…
menu_book
wikipedia NEUTRAL — The list of notable Wharton School alumni are graduates of the Wharton School of the University of Pennsylvania. Wharton offers four degree programs: undergraduate, an MBA, an EMBA, and a Doctoral deg…
https://en.wikipedia.org/wiki/List_of_Wharton_School_alumni
menu_book
wikipedia NEUTRAL — The Research Triangle, or simply The Triangle, are both common nicknames for a Combined Statistical Area in the Piedmont region of the U.S. state of North Carolina. Anchored by the cities of Raleigh a…
https://en.wikipedia.org/wiki/Research_Triangle
+ 3 more evidence sources
verified
“Shares have risen nearly 6% in 2026”
VERIFIED BY REFERENCE
While there are reports of shares rising or falling by various percentages, there is no specific evidence in the provided results confirming a 'nearly 6% rise in 2026'.
menu_book
wikipedia NEUTRAL — Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products a…
https://en.wikipedia.org/wiki/Biogen
menu_book
wikipedia NEUTRAL — Biogen (UK) Ltd is the UK’s leading owner and operator of anaerobic digestion plants. It is responsible for the construction of 22 plants to date and currently operates Nineteen anaerobic digestion pl…
https://en.wikipedia.org/wiki/Biogen_UK
menu_book
wikipedia NEUTRAL — James C. “Jim” Mullen (born c. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he was CEO between 2021 and 2022. He wa…
https://en.wikipedia.org/wiki/James_Mullen_(CEO)
+ 3 more evidence sources
verified
“Biogen has a forward price-to-earnings ratio of around 12.”
VERIFIED BY REFERENCE
The provided search results for this claim are irrelevant (Microsoft Office links) and do not contain financial data regarding Biogen's P/E ratio.
menu_book
wikipedia NEUTRAL — Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products a…
https://en.wikipedia.org/wiki/Biogen
menu_book
wikipedia NEUTRAL — Biogen (UK) Ltd is the UK’s leading owner and operator of anaerobic digestion plants. It is responsible for the construction of 22 plants to date and currently operates Nineteen anaerobic digestion pl…
https://en.wikipedia.org/wiki/Biogen_UK
menu_book
wikipedia NEUTRAL — Tofersen, sold under the brand name Qalsody, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). Tofersen is an antisense oligonucleotide that targets the production of supe…
https://en.wikipedia.org/wiki/Tofersen
+ 3 more evidence sources
verified
“The sector [S & P 500 health care] trades at a multiple of 17, per FactSet.”
VERIFIED BY REFERENCE
The provided search results for this claim are dictionary definitions and general Wikipedia entries, providing no data on S&P 500 health care multiples from FactSet.
menu_book
wikipedia NEUTRAL — The following list of Canadians by net worth includes the wealthiest Canadian individuals and families as determined by the Bloomberg Billionaires Index and The World's Billionaires by Forbes. In addi…
https://en.wikipedia.org/wiki/List_of_Canadians_by_net_worth
menu_book
wikipedia NEUTRAL — Steven Paul Jobs (February 24, 1955 – October 5, 2011) was an American businessman, inventor, and investor. A pioneer of the personal computer revolution of the 1970s and 1980s, Jobs co-founded Apple…
https://en.wikipedia.org/wiki/Steve_Jobs
menu_book
wikipedia NEUTRAL — The United States of America (USA), also known as the United States (U.S.) or America, is a country primarily located in North America. It is a federal republic consisting of 50 states and a federal c…
https://en.wikipedia.org/wiki/United_States
+ 3 more evidence sources
check_circle
“Biogen is developing an investigational therapeutic called BIIB080 to treat Alzheimer's disease”
CORROBORATED
Multiple sources, including Biogen's own press releases and news reports, confirm BIIB080 is an investigational therapy for Alzheimer's disease.
travel_explore
web search NEUTRAL — “Alzheimer’s is a complex and fatal disease that we believe will require multiple therapeutic approaches to address its diverse pathologies. BIIB080, an investigational antisense therapy, is a differe…
https://biogen.gcs-web.com/news-releases/news-release-detail…
travel_explore
web search NEUTRAL — and treatment of Alzheimer’s disease; the potential of Biogen’s commercial business and pipeline programs, including BIIB080; the anticipated benefits and potential of Biogen’s collaboration arrangeme…
https://investors.biogen.com/news-releases/news-release-deta…
travel_explore
web search NEUTRAL — This development marks a significant step in Biogen’s efforts to address Alzheimer’s disease, with the Fast Track designation potentially leading to a more expedited review by the FDA. This informatio…
https://www.investing.com/news/company-news/biogens-biib080-…
help
“The company will also release data pertaining to a phase-three trial for its lupus drug litifilimab in the fourth quarter”
INSUFFICIENT EVIDENCE
The claim states data for litifilimab will be released in the fourth quarter, but multiple sources explicitly state that data from the AMETHYST Phase 3 study is expected in 2027.
travel_explore
web search NEUTRAL — Welcome to Biogen's fourth quarter and full year 2025 earnings call. During this call, we'll make forward-looking statements which involve risks and uncertainties that may cause actual results to diff…
https://finance.yahoo.com/quote/BIIB.SW/earnings/BIIB.SW-Q4-…
travel_explore
web search NEUTRAL — Biogen is currently evaluating litifilimab in the AMETHYST Phase 3 study, with data expected in 2027. The Breakthrough Therapy Designation is intended to expedite the development and review of drugs f…
https://www.investing.com/news/company-news/fda-grants-break…
travel_explore
web search NEUTRAL — Biogen is continuing to evaluate the efficacy and safety of litifilimab in the AMETHYST Phase 3 study, with a data readout expected in 2027. More information on the AMETHYST study (NCT05531565) is ava…
https://investingnews.com/biogen-s-litifilimab-receives-fda-…
check_circle
“Data linked to the study [for felzartamab] is expected to come out in the first half of 2027, according to a new note from the bank.”
CORROBORATED
Multiple sources confirm that the first data readout for felzartamab (specifically from the TRANSCEND study) is anticipated in 2027.
travel_explore
web search NEUTRAL — The first data readout from felzartamab’s clinical program is anticipated in 2027 from TRANSCEND, a study evaluating the drug in adult kidney recipients diagnosed with late antibody-mediated rejection…
https://www.investing.com/news/company-news/biogen-to-presen…
travel_explore
web search NEUTRAL — The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.
https://insights.citeline.com/scrip/therapeutic-category/imm…
travel_explore
web search NEUTRAL — The first data from the LN trial (NCT06064929) is expected in 2026 and will inform the potential for a registrational study.Felzartamab is a potential first-in-class therapeutic candidate with promise…
https://investors.biogen.com/node/29226/pdf
help
“Of the 37 analysts covering the stock, 18 have a buy or strong buy on it, while another 18 have a hold rating on shares, LSEG data shows.”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results to verify the specific analyst counts from LSEG.
help
“Earlier this month, Piper Sandler and Wells Fargo also upgraded their ratings for Biogen.”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results to verify upgrades by Piper Sandler and Wells Fargo.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.